BG Medicine Goes Public, Begins Trading at $7 per Share

The diagnostics firm is offering 5 million shares with a target of $35 million in total proceeds – roughly 41 percent of the $86.3 million target the company gave when it filed to go public a year ago and 52 percent of the adjusted $67 million target it set in November.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.